Andrew Raubitschek, MD | Authors

Nightlite Pediatrics

Articles

Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas

December 01, 1998

The article by Dr. McLaughlin and coauthors provides both a useful summary of the clinical trials involving rituximab (IDEC C2B8 [Rituxan]) and a practical guide for its administration. Their review summarizes the most recent clinical results with this monoclonal antibody, which have just been published in the Journal of Clinical Oncology.[1] The review also includes a section on the potential mechanism of action of rituximab. Several areas merit comment.